Newsfeed

SEC meets to consider Emergency Use Authorisation request from Pfizer, SII and Bharat Biotech; to reconvene tomorrow

The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation, CDSCO met yesterday to consider the Emergency Use Authorisation request of Pfizer, Serum Institute of India (SII) and Bharat Biotech Private Limited.

Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech was perused and analysed by the SEC. The analysis of the additional data and information is going on. The meeting of SEC will convene again tomorrow.

 

Support Ethical Journalism. Support The Dispatch

The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism


 

The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies